Neuroinflammation
Ventus Therapeutics Continues Phase 2a Trial of VENT-02 NLRP3 Inhibitor in Parkinson’s Disease; No Indication of Program Halt
Ventus Therapeutics; VENT-02; NLRP3 inhibitor; Phase 2a trial; Parkinson’s disease; clinical development; neuroinflammation; biomarkers
“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”
Continuum Biologics, PIPE-791, Johnson & Johnson partnership, Initial Public Offering (IPO), Multiple sclerosis, Demyelinating diseases, Neuroinflammation, LPAR1 antagonist, Lysophosphatidic acid receptor Edg-2 antagonist